- Home
- CLPR vs ZURA Comparison
CLPR vs ZURA Comparison
Compare CLPR & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- ZURA
- Stock Information
- Founded
- CLPR 2015
- ZURA 2022
- Country
- CLPR United States
- ZURA United States
- Employees
- CLPR N/A
- ZURA N/A
- Industry
- CLPR Real Estate Investment Trusts
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLPR Real Estate
- ZURA Health Care
- Exchange
- CLPR Nasdaq
- ZURA Nasdaq
- Market Cap
- CLPR 57.8M
- ZURA 61.9M
- IPO Year
- CLPR 2017
- ZURA N/A
- Fundamental
- Price
- CLPR $3.90
- ZURA $1.13
- Analyst Decision
- CLPR
- ZURA Buy
- Analyst Count
- CLPR 0
- ZURA 7
- Target Price
- CLPR N/A
- ZURA $14.33
- AVG Volume (30 Days)
- CLPR 76.2K
- ZURA 533.4K
- Earning Date
- CLPR 07-31-2025
- ZURA 08-08-2025
- Dividend Yield
- CLPR 9.91%
- ZURA N/A
- EPS Growth
- CLPR N/A
- ZURA N/A
- EPS
- CLPR N/A
- ZURA N/A
- Revenue
- CLPR $152,413,000.00
- ZURA N/A
- Revenue This Year
- CLPR N/A
- ZURA N/A
- Revenue Next Year
- CLPR N/A
- ZURA N/A
- P/E Ratio
- CLPR N/A
- ZURA N/A
- Revenue Growth
- CLPR 8.63
- ZURA N/A
- 52 Week Low
- CLPR $3.38
- ZURA $0.97
- 52 Week High
- CLPR $7.12
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- CLPR 49.60
- ZURA 45.37
- Support Level
- CLPR $3.80
- ZURA $1.10
- Resistance Level
- CLPR $4.06
- ZURA $1.37
- Average True Range (ATR)
- CLPR 0.15
- ZURA 0.09
- MACD
- CLPR -0.01
- ZURA 0.00
- Stochastic Oscillator
- CLPR 29.17
- ZURA 37.18
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.